Treace Medical (TMCI) Q2 Revenue Up 7%

Treace Medical Concepts (NASDAQ:TMCI), a medical device company focused on innovative solutions for surgical bunion correction and other foot deformities, reported its latest earnings results on August 7, 2025, for Q2 FY2025. The most notable news was that revenue (GAAP) came in at $47.4 million, slightly ahead of analyst expectations, and Net losses (GAAP) narrowed year-over-year. The net loss per share (GAAP) of $(0.28) for Q2 2025 improved on the analyst forecast of $(0.29), and revenue (GAAP) also surpassed the $47.05 million consensus. While profitability remains elusive, the company showed stronger cost control and made meaningful progress in expanding its product portfolio. Overall, the period demonstrated modest revenue growth of 7%, better operating efficiency, and continued execution of its long-term strategy. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Treace Medical Concepts specializes in surgical systems and medical devices for the treatment of bunion and midfoot deformities. Its core product portfolio includes the Lapiplasty 3D Bunion Correction System, which offers correction of bunions in three dimensions, and a growing range of minimally invasive devices such as Nanoplasty, Percuplasty, and SpeedPlate implants. The company’s approach leverages technology and clinical evidence with an emphasis on precision and reproducibility for foot and ankle surgeons.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool